A Phase 1, Randomized, Open-label, Dose-Finding Study to Evaluate the Safety, Tolerability, and Reactogenicity of Escalating Doses of the Baiya SARS-CoV-2 Vax 1 Vaccine in Healthy Adults
Latest Information Update: 16 Jan 2023
At a glance
- Drugs Baiya SARS-CoV-2 Vax 1 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man
- Sponsors Baiya Phytopharm
- 11 Jan 2023 Status changed from recruiting to completed.
- 29 Oct 2021 Planned End Date changed from 1 Nov 2022 to 1 Feb 2023.
- 29 Oct 2021 Planned primary completion date changed from 1 Dec 2021 to 1 Mar 2022.